These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000086-35 A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ... bad-data
Completed, but no date, and reported results 2004-000087-27 A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ... bad-data
Reported results 2004-000088-92 A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Contusi... 2006-05-12 due-trials
Reported results 2004-000100-40 A Multicentre, randomised, double-blind, placebo controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of post-operative blee... 2007-11-29 due-trials
Completed, but no date, and reported results 2004-000514-38 4T study Treating to Target in Type 2 Diabetes A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a T... bad-data
Reported results 2004-001461-18 A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral a... 2006-03-01 due-trials
Exempt, with results 2004-001692-19 A single-centre, randomised, double-blind, cross-over trial comparing the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents... 2005-10-09 not-yet-due
Reported results 2004-002778-50 A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combin... 2006-03-24 due-trials
Reported results 2004-004202-24 Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Hae... 2007-01-31 due-trials
Completed, but no date, and reported results 2005-000042-37 Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit bad-data
Reported results 2005-000319-87 A 52 week, Open Labelled, Randomised multi-centre 2 Arm Parallel Group Trial comparing Efficacy and Safety of Insulin Aspart, given in a Fixed Dose Regimen or in a Flexible Regimen, with or without In... 2006-11-20 due-trials
Exempt, with results 2005-000891-42 A randomised, open-label, multi-centre trial investigating the intra-subject variability of ROTEM® and TEG® parameters following two intravenous administrations of the same dose of activated recombina... 2006-05-16 not-yet-due
Reported results 2005-000976-42 A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with ... 2006-12-21 due-trials
Completed, but no date, and reported results 2005-001522-88 A four-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once or twice daily in a basal-bolus regimen with insulin aspart in subjects wit... bad-data
Reported results 2005-002059-41 A multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy and safety of activated recombinant factor VII rFVIIa/NovoSeven/NiaStase in severely injur... 2008-11-09 due-trials
Reported results 2005-003414-15 Liraglutide Effect and Action in Diabetes LEAD-1 Effect on glycaemic control after once daily administration of liraglutide in combination with glimepiride versus glimepiride monotherapy versus ... 2007-06-30 due-trials
Reported results 2005-003415-71 Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycaemic control after once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and met... 2007-05-31 due-trials
Reported results 2005-003417-32 Efecto y acción de liraglutida en diabetes (LEAD-2): Efecto sobre el control glucémico tras la administración una vez al día de liraglutida en combinación con metformina frente a metformina en monoter... 2009-02-13 due-trials
Reported results 2005-003980-21 A Multinational, Open Label, Randomised, Three Period, Cross Over Trial Investigating The Impact Of Exercise And Type Of Basal Insulin Used On Blood Glucose Levels In Subjects With Type 1 Diabetes Tre... 2006-11-06 due-trials
Reported results 2005-005378-58 Inhaled pre-prandial human insulin with the AERx iDMS versus s.c. insulin aspart in type 2 diabetes A 52-week, open-label, multicentre, randomised trial followed by 52-week extension and 12-week re-r... 2008-06-16 due-trials
Reported results 2006-000051-18 A 52-Week, Multinational, Multi-Centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Children and Adolescents 2-16 years with Type 1 Diabet... 2009-04-01 due-trials
Reported results 2006-000796-15 Inhaled pre-prandial human insulin with the AERx® iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to investig... 2008-03-05 due-trials
Reported results 2006-001629-24 A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms. Tr... 2008-11-12 due-trials
Reported results 2006-002478-23 A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 years with Type 1 Diabetes on a Basal- Bolus Regimen with Insulin Aspart as Bo... 2009-09-07 due-trials
Completed, but no date, and reported results Terminated 2006-003060-59 A 32 week, national, single-centre, open-labelled, randomised, cross-over trial comparing energy expenditure with insulin detemir versus NPH insulin using a basal-bolus regimen with insulin aspart as ... bad-data
Reported results 2006-003148-51 A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Def... 2010-04-15 due-trials
Reported results 2006-003288-29 A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in c... 2008-04-10 due-trials
Reported results 2006-004481-13 Efecto de liraglutida sobre el peso corporal en sujetos obesos sin diabetes Ensayo de 20 semanas de duración, aleatorizado, doble ciego, controlado con placebo, en seis grupos paralelos, multicéntrico... 2009-04-30 due-trials
Completed, but no date, and reported results Terminated 2006-004622-81 Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel trial... bad-data
Reported results 2006-004623-12 Inhaled human insulin with the AERx® iDMS as prandial monotherapy compared to combination therapy with metformin and glimepiride in type 2 diabetes: an eighteen-week, open-label, multicentre, randomis... 2008-03-04 due-trials
Reported results 2006-004702-56 Outcome Trial Evaluating the Efficacy and Safety of Norditropin in Adult Patients on Chronic Haemodialysis A Randomised, Double-blind, Parallel group, Placebo controlled, Multi-centre trial Studio... 2009-12-19 due-trials
Completed, but no date, and reported results Terminated 2006-004731-29 Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: A 52-week, open-label, multicentr... bad-data
Reported results 2006-004733-15 A 12-months multi-national, multi-centre, double-blind, randomised, parallel safety and efficacy comparison of insulin detemir produced by the current process and insulin detemir produced by the NN729... 2008-07-09 due-trials
Reported results 2006-004861-33 A randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (Levemir®) versus human insulin (NPH insulin), used in combination with insulin as... 2010-08-05 due-trials
Reported results 2006-004879-35 A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haem... 2010-06-18 due-trials
Reported results 2006-005350-79 A single arm, single-centre, open-label, exploratory trial of recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymph n... 2008-06-25 due-trials
Exempt, with results Terminated 2006-005751-16 An open label, dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm t... 2008-06-30 not-yet-due
Reported results 2006-006092-21 Efecto y acción de liraglutida en diabetes (LEAD-6): efecto sobre el control glucémico de liraglutida o exenatida en combinación con metformina, sulfonilurea o ambas en sujetos con diabetes tipo 2. En... 2009-04-14 due-trials
Reported results 2006-006589-41 Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning ve... 2008-12-29 due-trials
Reported results 2006-006715-77 A randomised, multicentric, open labelled, parallel group trial with insulin aspart and insulin detemir, investigating the glycaemic effect and profile in children with Type 1 diabetes, of two separ... 2009-03-13 due-trials
Reported results 2007-000123-18 A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart (NovoRapid®) according to the largest meals (Basic Bas... 2009-05-06 due-trials
Reported results 2007-001506-25 An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Standard... 2009-01-07 due-trials
Reported results 2007-002462-35 A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metform... 2008-08-28 due-trials
Reported results 2007-002474-60 A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + NovoR... 2008-06-20 due-trials
Reported results 2007-002476-33 A 16 week randomised, open labelled, 3 armed, parallel group, treat-to-target trial comparing once daily injection of SIAC 30 (B), SIAC 45 (B) and insulin glargine, all in combination with metformin i... 2008-08-23 due-trials
Reported results 2007-003937-17 Efecto de liraglutida en comparación con sitagliptina, ambas en combinación con metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, con comparador activo, de tres g... 2010-06-03 due-trials
Reported results 2007-003956-12 Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metf... 2009-02-05 due-trials
Reported results 2007-005317-19 Efecto de insulina detemir en combinación con liraglutida y metformina en comparación con liraglutida y metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, de grupo... 2010-11-01 due-trials
Reported results 2008-001049-24 Efecto de liraglutida en el peso corporal en sujetos no diabéticos obesos o con sobrepeso y comorbilidad. Ensayo clínico aleatorizado, doble-ciego, controlado con placebo, grupos paralelos, multicéntr... 2015-06-26 due-trials
Reported results 2008-001050-40 A 26 week randomised, open labelled, parallel group, multi-national, treat-to-target trial comparing efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin ver... 2009-08-28 due-trials
Completed, but no date, and reported results 2008-001061-29 A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-... bad-data
Reported results 2008-001674-32 NordiNet International Outcome Study (NordiNet IOS) 2016-12-31 due-trials
Exempt, with results 2008-002157-21 A Multi-Centre, Multi-National, Open-Label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate in Subjects with Haemophilia A 2009-10-01 not-yet-due
Reported results 2008-002199-88 Efecto de liraglutida en el peso corporal en sujetos con sobrepeso u obesos con diabetes tipo 2. Ensayo clínico de 1 año de duración, aleatorizado, doble-ciego, controlado con placebo, con tres grupos... 2013-01-25 due-trials
Reported results 2008-003739-19 Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratam... 2010-08-10 due-trials
Reported results 2008-003960-20 A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy of ... 2011-09-21 due-trials
Reported results 2008-005767-34 A trial comparing efficacy and safety of NN5401 with insulin glargine, both in combination with oral antidiabetic drugs in subjects with type 2 diabetes 2010-10-25 due-trials
Reported results 2008-005768-15 A 26-week, randomised, open-labelled, two-arm, parallel-group, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) twice daily (BID) with biphasic insuli... 2010-08-23 due-trials
Reported results 2008-005769-71 A 26-week, multinational, multi-centre, open-labelled, two-arm, parallel, randomised, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) once daily plus... 2010-05-31 due-trials
Reported results 2008-005771-10 A 26 week randomised, controlled, open label, multicentre, multinational, three-arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either Soluble Insulin Ba... 2010-09-05 due-trials
Reported results 2008-005774-13 A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a b... 2010-12-08 due-trials
Reported results 2008-005776-27 A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing the efficacy and safety of SIBA and insulin glargine, both injected once daily in combination w... 2011-01-17 due-trials
Reported results 2008-005777-35 A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bol... 2010-11-05 due-trials
Reported results 2008-005945-46 Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects with Haemophilia A 2016-06-30 due-trials
Reported results 2008-006324-62 A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment with two different Doses of Recombinant Factor XIII following Cardiopulmonary Bypass S... 2011-02-23 due-trials
Reported results 2008-006424-54 An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (L... 2011-03-29 due-trials
Reported results 2008-007883-41 A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency 2015-10-20 due-trials
Reported results 2008-008240-25 A randomised, open-labelled, single dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) co... 2010-07-18 due-trials
Exempt, with results 2008-008306-43 A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults with Type 1 Diabetes 2010-05-03 not-yet-due
Reported results 2009-010662-28 A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes 2010-11-26 due-trials
Reported results 2009-011271-78 A trial comparing efficacy and safety of NN5401 with insulin glargine in insulin naive subjects with type 2 diabetes 2010-10-26 due-trials
Reported results 2009-011398-33 BEGIN™: EASY AM A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes 2010-11-18 due-trials
Reported results 2009-011399-31 BEGIN™: EASY PM A trial comparing the efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes 2010-12-01 due-trials
Reported results 2009-011672-29 A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen 2011-01-10 due-trials
Reported results 2009-011791-30 A randomised, double-blind, placebo-controlled, multiple dose trial of NNC 0151-0000-0000 in subjects with rheumatoid arthritis 2013-02-06 due-trials
Reported results 2009-012201-19 LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine ... 2015-12-17 due-trials
Reported results 2009-012923-27 Begin™: Flex T1. A 26-week trial investigating the dosing flexibility, efficacy and safety of NN1250 in subjects with type 1 diabetes with a 26-week extension. 2011-05-23 due-trials
Reported results Terminated 2009-013090-18 A 52-Week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Multinational Exploratory Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Evaluate The Ea... 2013-05-10 due-trials
Reported results 2009-013412-13 An extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes 2010-12-07 due-trials
Reported results 2009-014894-42 A 26-week randomised, controlled, open label, multicentre, multinational, treat to target trial investigating the impact of dietary intervention on weight change and the relationship between weight ch... 2011-11-14 due-trials
Reported results 2009-015721-36 An extension trial to NN1250-3585 investigating safety and efficacy of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen 2011-06-16 due-trials
Reported results 2009-015754-38 An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes 2011-12-20 due-trials
Reported results 2009-015755-24 An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes 2011-12-15 due-trials
Reported results 2009-015816-17 An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin � OADs in type 2 diabetes 2011-05-31 due-trials
Reported results 2009-015839-33 An extension trial comparing safety and efficacy of NN5401 with insulin glargine in subjects with type 2 diabetes 2011-05-04 due-trials
Reported results 2009-016383-36 A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A 2011-11-21 due-trials
Exempt, with results 2009-016779-31 A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults with Type 1 Diabetes 2010-11-12 not-yet-due
Reported results 2009-016869-28 A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Defici... 2011-10-07 due-trials
Reported results 2009-017387-16 To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy 2011-04-18 due-trials
Other 2009-017814-56 A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination wit... not-yet-due
Reported results 2010-018974-19 A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects with ... 2012-04-25 due-trials
Reported results 2010-019261-28 A randomised, single-dose, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC 0142-0000-0002 in subjects with active rheumatoid arthritis 2011-10-11 due-trials
Reported results 2010-020192-23 A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Paediatric Subjects with ... 2015-03-29 due-trials
Reported results 2010-020836-21 A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s d... 2013-05-23 due-trials
Exempt, with results 2010-021057-39 A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 Diabetes 2011-09-30 not-yet-due
Reported results 2010-021283-14 A randomised, double blind, placebo-controlled, multiple dose trial of Anti-IL-20 (109-0012) in subjects with rheumatoid arthritis 2012-03-12 due-trials
Reported results 2010-021560-15 A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec ... 2012-11-22 due-trials
Ongoing 2010-022304-50 A trial comparing the efficacy and safety of insulin degludec three times weekly in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms not-yet-due
Reported results 2010-022337-29 A trial comparing the efficacy and safety of insulin degludec once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms 2011-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-023069-24 A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0156 0000 0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemo... 2013-05-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023070-40 An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B 2013-12-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023072-17 Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B 2014-03-31 bad-data
Reported results 2010-023803-92 Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors 2012-08-13 due-trials
Exempt, with results 2010-023921-39 Multi-Centre, Open-Label, Randomised Trial Investigating the Pharmacokinetics of a Single Dose of NNC 0155-0000-0004 (N8) in Patients with Haemophilia A 2011-09-25 not-yet-due
Reported results 2010-024049-53 Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes 2015-06-11 due-trials
Reported results 2010-024051-93 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes 2015-01-22 due-trials
Reported results 2010-024054-11 Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes 2017-07-21 due-trials
Reported results 2010-024303-27 A 20 weeks randomised, multinational, open labelled, 2 armed, parallel group comparison of twice daily subject-driven titration of biphasic insulin aspart (BIAsp) 30 versus twice daily investigator-dr... 2012-07-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000826-31 Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B 2023-11-17 bad-data
Reported results 2011-001033-16 Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A 2018-12-05 due-trials
Reported results 2011-001142-15 A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A ... 2018-12-10 due-trials
Reported results 2011-001144-30 Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A Efficacia e sicurezza di NNC 0129-0000-1003 nel corso di interventi chirurgici in pazie... 2018-12-10 due-trials
Reported results 2011-001493-25 A trial comparing the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec, both in combination with metformin, in subjects with type 2... 2012-07-09 due-trials
Reported results 2011-001568-22 A multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis 2013-07-10 due-trials
Reported results 2011-001712-61 A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) and BIAsp 30 BID both with metformi... 2012-11-19 due-trials
Exempt, with results 2011-002104-32 A trial investigating the pharmacokinetic properties of FIAsp in children, adolescents and adults with type 1 diabetes not-yet-due
Reported results 2011-002336-72 A 26-weeks randomised, parallel two-arm, double-blind, multi-centre, multinational, treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide with insulin degludec in... 2012-10-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002605-29 Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes 2020-05-20 bad-data
Reported results 2011-002696-41 The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes 2013-10-22 due-trials
Trial is outside EEC, and reported results 2011-002949-35 This trial is a randomized, single-centre, double-blind, two-period cross-over glucose clamp trial to test for bioequivalence between two SIBA (IDeg) formulations in healthy subjects. This trial is p... bad-data
Reported results 2011-002968-24 Efficacy and safety of liraglutide versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment 2013-08-20 due-trials
Reported results 2011-003148-39 A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in children and adolescents 1 to less than 18 year... 2013-07-30 due-trials
Reported results 2011-004665-32 The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification 2014-02-14 due-trials
Reported results 2011-004930-33 A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in... 2013-10-18 due-trials
Reported results 2011-005376-42 A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis 2013-08-26 due-trials
Reported results 2012-000038-20 A randomised, double-blind, placebo-controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12 to 17 years 2014-05-26 due-trials
Reported results 2012-000140-97 The efficacy of insulin degludec/liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy 2013-10-23 due-trials
Reported results 2012-000209-63 The efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and OAD therapy 2014-03-11 due-trials
Reported results 2012-000373-23 A trial comparing the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart in subjects with type 2 diabetes mellitus previously treated with insulin glargine 2013-08-22 due-trials
Reported results 2012-000609-58 A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid... 2014-11-30 due-trials
Reported results 2012-000610-11 A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid... 2014-08-07 due-trials
Reported results 2012-001711-23 A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A Studio clinico... 2018-09-28 due-trials
Reported results 2012-001930-32 A randomised, double blind, cross-over trial comparing the safety and efficacy of insulin degludec and insulin glargine, both with insulin aspart as mealtime insulin in subjects with type 1 diabetes 2016-01-12 due-trials
Reported results 2012-002346-20 A 26-week trial comparing efficacy and safety of insulin degludec/insulin aspart BID and insulin degludec OD plus insulin aspart in subjects with type 2 Diabetes Mellitus treated with basal insulin in... 2014-01-09 due-trials
Reported results 2012-002432-93 A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn?s disease Estudio aleatorizado, doble ciego... 2014-12-19 due-trials
Reported results 2012-002839-28 A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes 2016-03-15 due-trials
Reported results 2012-003152-37 A randomised trial comparing efficacy and safety after intensification with either insulin aspart once daily as add-on or changing to basal bolus treatment with insulin degludec and insulin aspart in ... 2014-03-07 due-trials
Reported results 2012-003566-41 A trial investigating the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals versus insulin detemir once or twice daily plus meal time insuli... 2014-11-07 due-trials
Reported results 2012-003580-21 The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, mult... 2015-06-04 due-trials
Reported results 2012-004413-14 A trial comparing the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus. 2014-11-04 due-trials
Reported results 2012-004625-25 A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) in subjects with type 2 diabetes mellitus using two different titration algorithms 2015-12-23 due-trials
Reported results 2012-004826-92 Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes 2015-07-13 due-trials
Reported results 2012-004827-19 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes 2015-11-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004867-38 Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and effic... 2022-10-27 bad-data
Reported results 2012-004931-22 Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin A szitagliptinről liraglutidr... 2015-06-15 due-trials
Reported results 2012-004984-27 Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes 2014-11-19 due-trials
Reported results 2012-004994-16 Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes 2015-01-09 due-trials
Reported results 2012-005583-10 Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes Učinkovitost in varnost FIAsp v bazalno... 2014-11-17 due-trials
Reported results 2012-005778-74 The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes. A 26 week randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-cen... 2016-01-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000013-20 A randomised, open-labelled, active-controlled, multinational, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth ho... 2014-11-04 bad-data
Reported results 2013-000632-94 Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes 2015-05-13 due-trials
Reported results Terminated 2013-001492-20 A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with... 2014-08-11 due-trials
Reported results 2013-002233-37 A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjec... 2014-05-12 due-trials
Reported results 2013-002371-17 A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events 2016-10-31 due-trials
Reported results 2013-002878-47 A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin deglud... 2015-04-28 due-trials
Reported results 2013-002892-16 A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 ... 2018-05-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-004025-88 Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and ef... 2021-10-21 bad-data
Reported results 2013-004392-12 Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes 2015-09-03 due-trials
Reported results 2013-004502-26 Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes 2015-11-21 due-trials
Trial is outside EEC, and reported results 2013-004791-35 Efficacy and safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated Chinese patients with haemophilia A bad-data
Reported results 2013-005500-33 A 26-week open label, randomised, 2-armed, parallel group, multi-centre trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn in combination with metform... 2016-06-14 due-trials
Reported results 2014-000290-39 A multicentre, multinational, randomised, open-labelled, parallel-group, active-controlled trial to compare the safety of once weekly dosing of NNC0195-0092 with daily Norditropin® FlexPro® for 26 wee... 2016-01-04 due-trials
Reported results 2014-001215-39 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigatin... 2019-02-27 due-trials
Reported results 2014-001540-38 Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, multi-c... 2017-04-12 due-trials
Reported results 2014-002568-33 Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes 2018-03-05 due-trials
Reported results 2014-002716-16 An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral ... 2015-12-31 due-trials
Reported results 2014-003196-39 Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes. A 26-week, multicentre, double-blind, randomised, controlled dose-fi... 2016-10-13 due-trials
Reported results 2014-003621-18 DUAL?VII - Insulin degludec/liraglutide (IDegLira) vs. basal-bolus therapy: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in subj... 2016-10-05 due-trials
Reported results 2014-003708-62 A 32-week randomised, multinational, treat-to-target, open label, parallel group comparison of stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insul... 2016-09-21 due-trials
Reported results 2014-004353-14 Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26-we... 2019-08-08 due-trials
Reported results 2014-004415-37 Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double... 2020-11-19 due-trials
Trial is outside EEC, and reported results 2014-004454-34 A randomised, double-blind, placebo-controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of liraglutide in obese children aged 7 to 11 years bad-data
Reported results 2014-005375-91 Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes 2017-05-19 due-trials
Reported results 2014-005639-15 A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus 2018-10-03 due-trials
Listed as ongoing, but also has a completion date 2015-000531-32 A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to... 2024-09-26 bad-data
Reported results 2015-001047-36 Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 Diabetes 2017-08-18 due-trials
Reported results 2015-001351-71 Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes 2018-03-28 due-trials
Reported results 2015-001596-48 A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus 2017-10-23 due-trials
Reported results 2015-001919-13 Pharmacogenetic testing of saliva samples from patients with ≥5 exposure days to rFVIIa analogue in the adept™2 trial. Bio-specimen research study 2016-04-15 due-trials
Reported results 2015-002417-29 Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately co... 2019-08-12 due-trials
Trial is outside EEC, and reported results 2015-002613-30 A 12-month, open-labelled, randomised, parallel-group, multi-centre, interventional trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) therapy... bad-data
Reported results 2015-003563-10 A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes 2018-09-25 due-trials
Completed, but no date, and reported results 2015-004768-12 A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral... bad-data
Reported results 2015-005209-36 Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial 2018-03-08 due-trials
Reported results 2015-005210-30 Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial 2018-05-30 due-trials
Reported results 2015-005326-19 Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial 2018-05-15 due-trials
Exempt, with results 2015-005327-63 A multi-centre, comparative, double blind, randomised cross-over trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol... 2017-04-07 not-yet-due
Reported results 2015-005593-38 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. A 52 week Randomised, Open-label, Ac... 2019-03-27 due-trials
Reported results 2015-005619-33 Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin 2018-09-25 due-trials
Reported results 2015-005622-19 Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. A 26-week, randomised, double-blind, placebo-controlled trial 2017-12-08 due-trials
Reported results 2016-000510-30 A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors 2020-01-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-000614-29 A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without Inhibitors 2020-06-03 bad-data
Reported results 2016-000685-39 Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis A 72-week randomised, double-blind, place... 2020-03-19 due-trials
Reported results 2016-000878-38 Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in Combination with Insulin Degludec with or without Metformin in Adults with Type 2 Diabetes 2019-01-29 due-trials
Reported results 2016-000904-27 Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus. A 30-week randomised, double-blind, placebo-controlled trial 2018-08-06 due-trials
Reported results 2016-000988-16 Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes Mellitus treated with insulin - 52-week, randomised, double-blind, placebo-controlled trial 2018-08-22 due-trials
Reported results 2016-000989-35 Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetes 2018-11-16 due-trials
Exempt, with results 2016-002396-99 Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A 2018-10-15 not-yet-due
Reported results 2016-002801-20 A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral a... 2019-03-05 due-trials
Reported results 2016-003821-40 Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial 2019-06-19 due-trials
Reported results 2016-004965-22 Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes 2018-08-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-000048-17 A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes. 2020-12-17 bad-data
Trial is outside EEC, and reported results 2017-000914-47 A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for gestat... bad-data
Exempt, with results 2017-002014-31 A trial comparing the pharmacokinetic properties of fast-acting insulin aspart between children, adolescents and adults with type 1 diabetes 2018-07-05 not-yet-due
Trial is outside EEC, and reported results 2017-002281-46 Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India. bad-data
Reported results 2017-003219-20 Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-centre, ... 2021-02-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003380-35 SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity 2023-06-29 bad-data
Reported results 2017-003414-10 Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes 2020-05-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003436-36 Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity 2021-03-05 bad-data
Reported results 2017-003473-34 Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period 2020-03-20 due-trials
Other 2017-003619-20 Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes not-yet-due
Reported results 2017-003726-32 Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity A heti egyszeri 2,4 mg szemaglutid két éves hatásosságának és biztonságosságának vizsgálata túlsú... 2021-03-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003788-36 Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A 2020-12-03 bad-data
Reported results 2017-004047-20 A randomised, cross-over, open-label, multi-centre trial comparing the effect of insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 diabetes using flash glucos... 2019-12-27 due-trials
Ongoing 2018-000231-27 A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency not-yet-due
Listed as ongoing, but also has a completion date 2018-000232-10 A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no catch... 2020-03-05 bad-data
Reported results 2018-000322-63 An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inh... 2020-01-17 due-trials
Trial is outside EEC, and reported results 2018-000750-22 A trial investigating the long-term efficacy and safety of two doses of NN-220 (somatropin [genetical recombination]) in short stature due to Noonan syndrome bad-data
Listed as ongoing, but also has a completion date and reported results 2018-001945-14 Investigation of safety and efficacy of NNC0174-0833 for weight management – a dose finding trial 2021-03-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-002431-18 Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity 2022-03-28 bad-data
Reported results 2018-002589-38 PIONEER 12 China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin 2021-10-27 due-trials
Reported results 2018-002590-22 China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only PIONEER 11 Kína, több régió... 2021-10-27 due-trials
Listed as ongoing, but also has a completion date 2018-002878-50 Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease 2024-01-09 bad-data
Ongoing 2018-002952-34 Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes not-yet-due
Ongoing 2018-003099-10 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria not-yet-due
Listed as ongoing, but also has a completion date 2018-003141-42 Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes 2024-09-10 bad-data
Reported results 2018-003406-11 A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in insulin-naïve ... 2020-01-17 due-trials
Reported results 2018-003407-18 A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin ... 2020-01-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-004484-31 Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis 2021-06-10 bad-data
Reported results 2018-004529-96 Efficacy and safety of semaglutide 2.0 mg s.c. once-weekly compared to semaglutide 1.0 mg s.c. once-weekly in subjects with type 2 diabetes 2020-11-09 due-trials
Listed as ongoing, but also has a completion date 2018-004889-34 Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors 2022-06-07 bad-data
Ongoing 2018-004891-36 Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors not-yet-due
Exempt, with results 2019-000465-20 Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (Mim8) in healthy subjects and in subjects with haemophilia A with or without fact... 2023-10-06 not-yet-due
Reported results 2019-002284-10 A TRIAL TO COMPARE THE INJECTION SITE EXPERIENCE OF 0.25 MG SEMAGLUTIDE SC ADMINISTERED BY 2 DIFFERENT PRODUCTS 2019-10-08 due-trials
Reported results Terminated 2019-002641-37 Efficacy and safety of once-weekly subcutaneous administration of concizumab prophylaxis in patients with haemophilia A and B, with or without inhibitors 2020-03-26 due-trials
Completed, report not yet due 2019-003399-38 Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease 2024-07-12 not-yet-due
Reported results 2019-003654-83 A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF 0.25 MG SEMAGLUTIDE B AND SEMAGLUTIDE D ADMINISTERED SC 2020-01-04 due-trials
Reported results 2019-003844-57 A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF SEMAGLUTIDE 0.25 MG AND DULAGLUTIDE 0.75 MG ADMINISTERED SC 2020-02-26 due-trials
Reported results Terminated 2019-004234-42 Effect and safety of two different dose-escalation regimens for once-weekly semaglutide s.c. in subjects with type 2 diabetes mellitus previously treated with GLP-1 RAs 2020-06-24 due-trials
Reported results 2019-004452-11 Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction 2023-04-18 due-trials
Other 2019-004594-44 The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis not-yet-due
Reported results 2020-000204-11 Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis 2023-09-08 due-trials
Reported results 2020-000299-39 Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes 2023-03-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-000442-34 A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin naï... 2022-12-01 bad-data
Reported results 2020-000454-10 A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes tr... 2022-05-16 due-trials
Reported results 2020-000472-37 A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-dia... 2022-06-23 due-trials
Reported results 2020-000474-16 A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-diab... 2022-06-16 due-trials
Reported results 2020-000476-38 Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting 2022-08-29 due-trials
Other 2020-000504-11 Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors not-yet-due
Other 2020-000546-34 Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial not-yet-due
Ongoing 2020-000828-19 REMODEL - Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease Studio clinico REMODEL– Meccanismo di azione a livello renale di semaglutide in pazienti co... not-yet-due
Ongoing 2020-001048-24 A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors. not-yet-due
Reported results 2020-002374-27 Efficacy and safety of once weekly insulin icodec compared to once daily insulin degludec 100 units/mL, both in combination with insulin aspart, in adults with type 1 diabetes. A 26-week, randomised,... 2022-12-02 due-trials
Reported results 2020-002630-32 Dose response and safety of an oral PCSK9i, NNC0385-0434, in patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk on maximally tolerated statin dose and other lipid-l... 2022-06-20 due-trials
Other 2020-002826-97 A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-002939-29 Efficacy and safety of subcutaneous semaglutide 2.4 mg once-weekly in subjects with obesity and prediabetes 2023-07-14 bad-data
Reported results 2020-002953-11 Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity 2023-06-12 due-trials
Trial is outside EEC, and reported results 2020-002974-28 A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency bad-data
Trial is outside EEC, and reported results 2020-003001-58 A multi-centre, open-label trial evaluating efficacy, safety and pharmacokinetics of turoctocog alfa pegol (N8-GP) when used for treatment and prophylaxis of bleeding episodes in previously treated Ch... bad-data
Listed as ongoing, but also has a completion date and reported results 2020-003313-35 A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 Ant... 2024-04-16 bad-data
Listed as ongoing, but also has a completion date 2020-003467-26 Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors 2024-11-13 bad-data
Other 2020-003485-39 A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease not-yet-due
Other 2020-003566-39 Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-004170-22 Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes 2023-10-11 bad-data
Other 2020-004848-29 A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) not-yet-due
Other 2020-004853-59 ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-004863-14 Investigation of the safety and efficacy of semaglutide s.c. in combination with NNC0480-0389 in participants with type 2 diabetes – a dose finding study 2023-03-23 bad-data
Other 2020-004864-25 A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) not-yet-due
Completed, report not yet due 2020-005281-34 A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabe... 2024-04-23 not-yet-due
Completed, report not yet due 2020-005308-21 A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes... 2024-01-16 not-yet-due
Completed, reported early 2020-005309-18 A 52 week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti diabetic dr... 2023-11-14 not-yet-due
Other 2020-005435-75 Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity Efficacia e sicurez... not-yet-due
Reported results 2021-001501-69 Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants with Type 2 Diabetes Klinické skúš... 2023-09-18 due-trials
Other 2021-004392-13 Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight not-yet-due
Trial is outside EEC, and reported results 2021-004947-25 A multi-centre, open-label trial evaluating efficacy, safety and pharmacokinetics of nonacog beta pegol when used for treatment and prophylaxis of bleeding episodes in Chinese patients with haemophi... bad-data
Other 2021-005121-24 Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants withoverweight or obesityand type 2 diabetes not-yet-due
Ongoing 2021-005607-13 A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with sho... not-yet-due
Other 2021-005855-35 The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascula... not-yet-due
Other 2021-006226-49 ATTR CM - Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy ATTR CM - Efficacia e sicurezza di NNC6019-0001 a due dosaggi diversi in s... not-yet-due
Completed, report not yet due 2021-006534-40 Efficacy and safety of oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4) 2024-05-07 not-yet-due
Ongoing 2022-000790-94 Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity. not-yet-due
Completed, report not yet due 2022-000882-41 Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study 2023-12-13 not-yet-due
Ongoing 2022-002235-60 Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes not-yet-due
Other 2022-003384-24 A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheim... not-yet-due